Recruiting PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT06488625

Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Moderately Active Ulcerative Colitis

A Phase II/III, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) for Induction and Maintenance Therapy in Patients with Mild to Moderately Active Ulcerative Colitis

Sponsor: Ced Service GmbH

Conditions Ulcerative Colitis, Unspecified

Interventions 0 g/d CICR-NAM (blinded) High-Dose CICR-NAM Low-Dose CICR-NAM Open-Label

Updated 3 times since 2024 Last updated: Nov 4, 2024 Started: Sep 12, 2024 Primary completion: Oct 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Ulcerative Colitis, Unspecified and is currently actively recruiting participants. Ced Service GmbH leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE2/PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ced Service GmbH
German Federal Ministry of Education and Research
Gesellschaft für Therapieforschung mbH
University Hospital Schleswig-Holstein

Data source: University Hospital Schleswig-Holstein

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kiel, Germany